<DOC>
	<DOCNO>NCT03027375</DOCNO>
	<brief_summary>This trial ass efficacy safety QSG CHF .</brief_summary>
	<brief_title>Evaluating Safety Efficacy Qishen Granules Among Patients With Chronic Heart Failure</brief_title>
	<detailed_description>Background : Chronic heart failure ( CHF ) , final stage various cardiovascular disease , major public health problem associate significant hospitalization rate , mortality , huge health care cost , despite advance treatment management heart failure heart failure relate risk factor . Qishen granule ( QSG ) , Chinese herbal formula , widely use traditional chinese medicine ( TCM ) practitioners treat CHF . Several animal experimental study show QSG significantly relieve heart failure symptom CHF rat model . However , yet standard clinical trial ass . Thus , investigator conduct study evaluate efficacy safety QSG large , varied population . Methods/Design : This study design randomize , multi-center , placebo-controlled , double-blind , parallel-group clinical trial . An establish total 200 patient CHF recruit randomly allocate either QSG treatment group placebo group ( 1:1 ratio ) . The patient receive QSG placebo granule twice daily 12 week . The primary endpoint reduction percent change plasma N-terminal pro-B-type natriuretic peptide ( NT-proBNP ) level 12 week treatment . The secondary endpoint consist composite cardiac event ( CCEs ) , New York Heart Association ( NYHA ) functional classification , 6-minute walking distance ( 6MWD ) , Left ventricular ejection fraction , patient quality life TCM syndrome integral scale . Discussion : This trial ass efficacy safety QSG CHF .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>1. age 18 75 year ; 2. clinical finding CHF least 3 month prior screen ; 3 . CHF cause coronary heart disease hypertension , diagnose accord Chinese guideline publish 2014 diagnosis management CHF ; 4. clinically stable condition NYHA functional class II III optimal medical treatment fix dosage least 2 week ; 5. document leave ventricular ejection fraction ( LVEF ) ≤40 % serum NTproBNP level ≥450 pg/ml ; 6 . CHF Qi deficiency blood stasis syndrome ; 7. provision write informed consent . 1 . CHF complicate severe valvular disease , congenital heart disease , pericardial disease , cardiomyopathy , unstable angina , acute myocardial infarction ( recent 4 week ) , cardiogenic shock , acute myocarditis , infective endocarditis , uncontrolled severe cardiac arrhythmia hemodynamic change ; 2. pulmonary heart disease , pulmonary hypertension cause acute chronic pulmonary embolism cerebral apoplexy recent 6 month ; 3. severe hepatic inadequacy alanine aminotransferase alkaline phosphatase level &gt; 2 time upper normal limit , renal inadequacy creatinine clearance rate＞20 % serum creatinine level＞3mg/dl ( ＞265μmol/L ) , severe electrolyte imbalance , severe hematologic disease , malignant tumor , diabetes mellitus severe complication , severe endocrine disease hyperthyroidism hypothyroidism ; 4. acute infection confirm one follow 3 tip : 1 ) fever ; 2 ) white blood cell count＞10×109/L percentage neutrophils＞85 % ; 3 ) shadow chest Xray ; 5. uncontrolled blood pressure fibrosis organ ; 6 . CHF yin deficiency accord TCM syndrome differentiation ; 7. pregnancy breastfeeding ; 8. psychiatric infectious disease ; 9. patient participate clinical trial past two month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>traditional Chinese medicine</keyword>
	<keyword>Qishen granule</keyword>
</DOC>